Predictive and prognostic factors in patients with anaplastic lymphoma kinase rearranged early-stage lung adenocarcinoma.

IF 3.1 2区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS European Journal of Cardio-Thoracic Surgery Pub Date : 2024-11-04 DOI:10.1093/ejcts/ezae406
Filippo Tommaso Gallina, Fabiana Letizia Cecere, Riccardo Tajè, Luca Bertolaccini, Monica Casiraghi, Lorenzo Spaggiari, Giorgio Cannone, Alberto Busetto, Federico Rea, Nicola Martucci, Giuseppe De Luca, Edoardo Mercadante, Francesca Mazzoni, Stefano Bongiolatti, Luca Voltolini, Enrico Melis, Isabella Sperduti, Federico Cappuzzo, Roni Rayes, Lorenzo Ferri, Francesco Facciolo, Jonathan Spicer
{"title":"Predictive and prognostic factors in patients with anaplastic lymphoma kinase rearranged early-stage lung adenocarcinoma.","authors":"Filippo Tommaso Gallina, Fabiana Letizia Cecere, Riccardo Tajè, Luca Bertolaccini, Monica Casiraghi, Lorenzo Spaggiari, Giorgio Cannone, Alberto Busetto, Federico Rea, Nicola Martucci, Giuseppe De Luca, Edoardo Mercadante, Francesca Mazzoni, Stefano Bongiolatti, Luca Voltolini, Enrico Melis, Isabella Sperduti, Federico Cappuzzo, Roni Rayes, Lorenzo Ferri, Francesco Facciolo, Jonathan Spicer","doi":"10.1093/ejcts/ezae406","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to evaluate the predictive and prognostic factors in clinical stage I, anaplastic lymphoma kinase (ALK)-rearranged lung adenocarcinoma following radical surgery. Additionally, it sought to compare these factors with an external cohort of ALK wild-type patients.</p><p><strong>Methods: </strong>A multicentric, retrospective, case-control analysis was conducted on patients with clinical T1-2 N0 ALK-rearranged lung adenocarcinoma who underwent anatomical resection and radical lymphadenectomy. Data were collected from 5 high-volume oncological centres. An external cohort of ALK wild-type patients was also analysed for comparison. Survival analyses were performed using the Kaplan-Meier method, and multivariable Cox regression analysis was used to identify prognostic factors.</p><p><strong>Results: </strong>From January 2016 to December 2022, 63 patients with ALK-rearranged lung adenocarcinoma were included. High-grade tumours (G3) significantly associated with upstaging (odds ratio = 3.904, P = 0.04). Disease-free survival (DFS) and overall survival were significantly improved in upstaged patients receiving adjuvant treatment [hazard ratio (HR) = 0.18, P = 0.0042; HR = 0.24, P = 0.0004, respectively]. The solid or micropapillary histological subtypes were independently associated with worse DFS (HR = 3.41, P = 0.022). Comparison with 435 ALK wild-type patients showed worse DFS in the ALK-rearranged group (HR = 2.09, P = 0.0003). ALK-rearranged patients had higher rates of nodal upstaging, systemic and brain recurrences.</p><p><strong>Conclusions: </strong>Clinical T1-2 N0 ALK-rearranged lung adenocarcinoma is an aggressive disease with a specific tropism for lymph nodes and the brain. High-grade tumours are predictive of nodal upstaging. Adjuvant treatment significantly improves DFS and overall survival in upstaged patients, highlighting the need for personalized preoperative staging and post-surgical management in this cohort.</p>","PeriodicalId":11938,"journal":{"name":"European Journal of Cardio-Thoracic Surgery","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cardio-Thoracic Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ejcts/ezae406","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: This study aimed to evaluate the predictive and prognostic factors in clinical stage I, anaplastic lymphoma kinase (ALK)-rearranged lung adenocarcinoma following radical surgery. Additionally, it sought to compare these factors with an external cohort of ALK wild-type patients.

Methods: A multicentric, retrospective, case-control analysis was conducted on patients with clinical T1-2 N0 ALK-rearranged lung adenocarcinoma who underwent anatomical resection and radical lymphadenectomy. Data were collected from 5 high-volume oncological centres. An external cohort of ALK wild-type patients was also analysed for comparison. Survival analyses were performed using the Kaplan-Meier method, and multivariable Cox regression analysis was used to identify prognostic factors.

Results: From January 2016 to December 2022, 63 patients with ALK-rearranged lung adenocarcinoma were included. High-grade tumours (G3) significantly associated with upstaging (odds ratio = 3.904, P = 0.04). Disease-free survival (DFS) and overall survival were significantly improved in upstaged patients receiving adjuvant treatment [hazard ratio (HR) = 0.18, P = 0.0042; HR = 0.24, P = 0.0004, respectively]. The solid or micropapillary histological subtypes were independently associated with worse DFS (HR = 3.41, P = 0.022). Comparison with 435 ALK wild-type patients showed worse DFS in the ALK-rearranged group (HR = 2.09, P = 0.0003). ALK-rearranged patients had higher rates of nodal upstaging, systemic and brain recurrences.

Conclusions: Clinical T1-2 N0 ALK-rearranged lung adenocarcinoma is an aggressive disease with a specific tropism for lymph nodes and the brain. High-grade tumours are predictive of nodal upstaging. Adjuvant treatment significantly improves DFS and overall survival in upstaged patients, highlighting the need for personalized preoperative staging and post-surgical management in this cohort.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Anaplastic Lymphoma Kinase: rearranged 早期肺腺癌患者的预测因素和预后因素。
研究目的本研究旨在评估临床I期、ALK重组肺腺癌根治术后的预测和预后因素。此外,研究还试图将这些因素与外部的 ALK 野生型患者队列进行比较:对临床上接受解剖切除术和根治性淋巴结切除术的T1-2 N0 ALK重组肺腺癌患者进行了多中心、回顾性病例对照分析。数据收集自五个高容量肿瘤中心。同时还分析了一组外部的ALK野生型患者进行比较。采用Kaplan-Meier法进行生存分析,并使用多变量Cox回归分析确定预后因素:从2016年1月至2022年12月,共纳入63例ALK重排肺腺癌患者。高级别肿瘤(G3)与上行分期显著相关(OR=3.904,P=0.04)。接受辅助治疗的上分期患者的 DFS 和 OS 明显改善(分别为 HR = 0.18,p = 0.0042;HR = 0.24,p = 0.0004)。实性或微乳头组织学亚型与较差的DFS独立相关(HR = 3.41,p = 0.022)。与435例ALK WT患者相比,ALK重组组的DFS更差(HR = 2.09,p = 0.0003)。ALK重组患者的结节上移率、全身复发率和脑复发率更高:临床上,T1-2 N0 ALK重排肺腺癌是一种侵袭性疾病,对淋巴结和脑部有特殊的滋养作用。高级别肿瘤可预测结节上移。辅助治疗可明显改善分期上调患者的DFS和OS,突出了对这部分患者进行个性化术前分期和术后管理的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.60
自引率
11.80%
发文量
564
审稿时长
2 months
期刊介绍: The primary aim of the European Journal of Cardio-Thoracic Surgery is to provide a medium for the publication of high-quality original scientific reports documenting progress in cardiac and thoracic surgery. The journal publishes reports of significant clinical and experimental advances related to surgery of the heart, the great vessels and the chest. The European Journal of Cardio-Thoracic Surgery is an international journal and accepts submissions from all regions. The journal is supported by a number of leading European societies.
期刊最新文献
The effect of diabetes on long-term outcomes in patients following coronary artery bypass grafting. Comparison of bioprosthetic valves in primary isolated aortic valve replacement: a nationwide study. Serial changes of systemic ventricular function and atrioventricular valve function in patients with failing fontan. Funnelling the funnel chest debate into evidence-based care: current landscape of pectus excavatum surgery. Sarcopenia and malnutrition: worthwhile prehabilitation targets?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1